Biomedical Advanced Research and Development Authority (BARDA)

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory and critical care conditions including respiratory depression caused by drug overdose, post-surgery, and pathogens.

Care Access Research provides clinical research and clinical trial services. Care Access Research goal is to engage every healthcare professional in clinical research and to make clinical trials a care option for every patient.

CastleVax operates as a clinical-stage vaccine research company. CastleVax is reimagining how to provide safe and effective vaccines for all humans, everywhere.

Walgreens is the nation's largest drugstore chain with fiscal 2010 sales of $67 billion. The company operates 7,689 drugstores in all 50 states, the District of Columbia and Puerto Rico. Each day, Walgreens provides nearly 6 million customers the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services, and advice in communities across America. Walgreens scope of pharmacy services includes retail, specialty, infusion, medical facility, and mail service, along with respiratory services. These services improve health outcomes and lower costs for payers including employers, managed care organizations, health systems, pharmacy benefit managers, and the public sector. Take Care Health Systems is a Walgreens subsidiary that is the largest and most comprehensive manager of worksite health centers and in-store convenient care clinics, with more than 700 locations throughout the country.

Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases. It develops multiple antibiotic drugs intended to combat antimicrobial resistance. The company's technology is focused on targeting the treatment of infectious diseases for both inpatient and outpatient cases, deep expertise in the discovery, development and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance, enabling medical businesses optimal use of products and critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. It was founded in 2018 and is headquartered in San Diego, California.

ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

Battelle is the world's largest, independent research and development organization, working to advance scientific discovery and application. They're accelerating innovation by bringing people, science and technology together.

Draper is a non-profit laboratory focused on applied research, engineering development, education, and technology transfer. The laboratory provides engineering services directly to governments, industries, and academies; works on teams as a prime contractor or subcontractor; and participates as a collaborator in consortia. It also offers unbiased assessments of technology or systems designed or recommended by other organizations. Additionally, Draper is specialized in precision instrumentation; fault-tolerant, secure and assured, and autonomous systems; image and data analytics; human systems technology; materials engineering and microfabrication; and biomedical solutions. Draper was founded in 1973 and is based in Cambridge, Massachusetts.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Rivanna Medical, LLC is a medical technology company based in Charlottesville, Virginia, founded in 2010. The company focuses on developing and commercializing innovative ultrasound-based systems aimed at enhancing the application of spinal and epidural anesthesia through advanced 3D navigation of the lumbar spine. Its flagship product, Accuro, not only facilitates precise anesthesia delivery but also supports various diagnostic imaging needs, including musculoskeletal and abdominal anatomies. Rivanna Medical is committed to improving patient outcomes and lowering healthcare costs while minimizing patient exposure to radiation commonly associated with X-ray-based imaging techniques.

Aptitude Medical Systems provides the next generation of diagnostic testing, delivering lab-quality results quickly and easily wherever people need them. The company's mission is to combine the sensitivity and specificity of lab-based PCR tests with the cost-effectiveness and scalability of antigen tests. The company has developed proprietary synthetic molecules, known as aptamers, which enhance molecular recognition capabilities beyond traditional antibody technologies. This innovation enables early detection and treatment of diseases such as cancer, autoimmune disorders, and heart disease.

The Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are disproportionately affected by infectious diseases. The organization focuses on developing innovative vaccines aimed at preventing a wide range of illnesses, ensuring that these vital health resources are available to communities worldwide. By emphasizing the importance of immunization coverage, the Sabin Vaccine Institute seeks to improve overall healthcare outcomes and contribute to the prevention of diseases on a global scale.

OraSure Technologies, Inc. develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices used for detecting critical medical conditions. The company operates primarily in two segments, focusing on a diverse range of products that include rapid tests for HIV, HCV, and Ebola, as well as drug testing and alcohol testing solutions. Notable offerings include the OraQuick Rapid HIV test, the Intercept Oral Fluid Drug Testing System, and the Q.E.D. Saliva Alcohol Test. Additionally, OraSure provides genomic products through its subsidiary, DNA Genotek, which specializes in oral fluid sample collection for molecular diagnostics. The company's products cater to clinical laboratories, hospitals, community organizations, and government agencies, and are available in pharmacies across multiple continents. Founded in 2000 and headquartered in Bethlehem, Pennsylvania, OraSure Technologies is committed to advancing diagnostic solutions and improving public health outcomes.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory and critical care conditions including respiratory depression caused by drug overdose, post-surgery, and pathogens.

The Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are disproportionately affected by infectious diseases. The organization focuses on developing innovative vaccines aimed at preventing a wide range of illnesses, ensuring that these vital health resources are available to communities worldwide. By emphasizing the importance of immunization coverage, the Sabin Vaccine Institute seeks to improve overall healthcare outcomes and contribute to the prevention of diseases on a global scale.

Arcturus Therapeutics is an RNA medicines company headquartered in San Diego, California, specializing in the development of novel therapies for liver and respiratory diseases, as well as other rare conditions. Founded in 2013, the company utilizes its proprietary Self-Transcribing and Replicating RNA (STARR) technology and Unlocked Nucleic Acid (UNA) chemistry to create RNA therapeutics, including mRNA compounds aimed at treating specific genetic disorders. Its product pipeline features several key programs, including LUNAR-OTC for ornithine transcarbamylase deficiency, LUNAR-CF for cystic fibrosis, and LUNAR-COV19, a vaccine developed to combat the Coronavirus outbreak. Arcturus holds a substantial patent portfolio covering its technologies and has established collaborations with various pharmaceutical partners to advance its therapeutic candidates and vaccine development.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

EverGlade Consulting is a national consulting firm that offers management consulting solutions. The firm provides government funding, product development, litigation support, CHIPS funding applications, and DOE Loan Program application support solutions. It helps clients navigate the federal landscape. Its company incorporates market-based analytics based on industry, allowing us to focus more on organizational operations.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company creates single-use, handheld testing kits that provide instrument-free results for various conditions, including COVID-19 and sexually transmitted infections. Visby Medical aims to redefine illness testing and treatment through a human-centric approach, focusing on accuracy and user experience. In addition to its diagnostic products, the company offers a mobile health care platform that encompasses health information, risk assessment, electronic medical records, and remote medical advice services, catering to governments, NGOs, and private health providers.

Stevanato Group is a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

Opiant Pharmaceuticals is a specialty pharmaceutical company based in Santa Monica, California, focused on developing treatments for addictions and drug overdoses. The company is known for its NARCAN nasal spray, which is used to reverse opioid overdoses. Opiant's product pipeline includes therapies for opioid overdose, alcohol use disorder, acute cannabinoid overdose, and other substance use disorders. Founded in 2005 and formerly known as Lightlake Therapeutics, Opiant employs a team of addiction experts and utilizes intranasal and injectable delivery technologies for its treatments. The company primarily generates revenue through royalties and licensing agreements.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company’s leading product candidate, tebipenem pivoxil hydrobromide, is an oral antibiotic designed to treat MDR Gram-negative infections in adults. Additionally, Spero is advancing SPR206, an intravenous agent targeting MDR Gram-negative infections, and SPR720, an oral antibiotic aimed at treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics collaborates with various organizations, including Meiji Seika Pharma for tebipenem HBr, Everest Medicines for SPR206 in Asia, and the Bill & Melinda Gates Medical Research Institute for SPR720. Founded in 2013, Spero leverages a strong team in chemistry and microbiology to address significant unmet medical needs in infectious disease treatment.

Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep. Consumers can track five key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. The Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company creates single-use, handheld testing kits that provide instrument-free results for various conditions, including COVID-19 and sexually transmitted infections. Visby Medical aims to redefine illness testing and treatment through a human-centric approach, focusing on accuracy and user experience. In addition to its diagnostic products, the company offers a mobile health care platform that encompasses health information, risk assessment, electronic medical records, and remote medical advice services, catering to governments, NGOs, and private health providers.

First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.

QuidelOrtho is a diagnostics company based in San Diego, California, established in 1937. It specializes in the development, manufacturing, and marketing of point-of-care diagnostic solutions for infectious diseases, reproductive health, and women's health. The company offers a range of diagnostic tests under various brand names, including QuickVue and MicroVue, addressing conditions such as influenza, strep throat, pregnancy, and bacterial vaginosis. Additionally, QuidelOrtho provides immunoassay tests for detecting blood in stool samples and serological tests for Helicobacter pylori. Its products are utilized in physician offices, hospitals, clinical laboratories, and wellness screening centers, distributed through a network of national and regional distributors as well as a direct sales force primarily in the United States and internationally in regions like Japan, Europe, and the Middle East. The company also collaborates with BioHelix Corporation to develop in vitro molecular diagnostic tests using isothermal amplification technology. QuidelOrtho generates a significant portion of its revenue from the North American market while maintaining a presence in EMEA, China, and other regions.

Corning Incorporated, headquartered in Corning, New York, is a global leader in manufacturing glass, ceramics, and related materials. Established in 1851, the company operates across several segments, including Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment produces glass substrates for organic light-emitting diodes and liquid crystal displays utilized in televisions and computers. In Optical Communications, Corning provides optical fibers, cables, and various hardware solutions for telecommunications networks. The Environmental Technologies segment focuses on emissions control products for the automotive sector, while Specialty Materials includes advanced formulations for glass and ceramics. The Life Sciences segment offers laboratory products, including consumables and pharmaceutical glass packaging. Corning also develops Gorilla Glass for mobile devices and collaborates with companies like Intel Corporation to enhance technology solutions. Through its diverse product offerings, Corning aims to meet evolving market demands and support innovation in dynamic industries.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Vela Diagnostics Pte. Ltd. provides multipurpose utility for sample lysis, nucleic acid extraction, and polymerase chain reaction (PCR).

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.

Emergent BioSolutions is a global life sciences company that is driven by a mission to protect and enhance life. It develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep. Consumers can track five key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. The Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

Paratek Pharmaceuticals is a biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in developing and commercializing innovative therapies targeting life-threatening diseases and public health threats for civilian and military use. Its lead products include NUZYRA (omadacycline), a broad-spectrum antibiotic available in both oral and intravenous formulations, designed for treating community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another key product is SEYSARA (sarecycline), developed for the treatment of moderate to severe acne vulgaris. Paratek's research is grounded in novel tetracycline chemistry, and the company has received Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration for its antibiotic candidates. Additionally, Paratek has established collaborative agreements with various organizations, including Tufts University and the U.S. Army Medical Research Institute of Infectious Diseases, to advance its drug development efforts.

GenMark Diagnostics is a molecular diagnostics company specializing in the development and commercialization of innovative testing systems that utilize proprietary eSensor electrochemical detection technology. The company offers the ePlex instrument, which combines automated nucleic acid extraction and amplification, allowing for rapid testing of respiratory pathogens by placing patient samples directly into disposable test cartridges. Additionally, GenMark provides the XT-8 System, which has received FDA clearance and can analyze up to 24 test cartridges simultaneously, producing results within 30 minutes of receiving a sample. This system supports a variety of diagnostic tests, including those for respiratory viruses, cystic fibrosis, and hepatitis C genotyping. GenMark Diagnostics sells its products through direct sales and specialized service organizations in the United States and Europe, and is headquartered in Carlsbad, California. The company is also working on the next-generation AD-8 System, which aims to further streamline the testing process by integrating DNA amplification with its sensor detection technology.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. The company focuses on treating Clostridium difficile infection (CDI), with its lead product candidate, ridinilazole, currently in Phase III clinical trials. In addition to ridinilazole, Summit Therapeutics is developing the DDS-01 series aimed at treating infections caused by Neisseria gonorrhoeae and the DDS-04 series for Enterobacteriaceae. The company operates primarily in the United States, Latin America, and Europe, with the intention of establishing new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, Summit Therapeutics is positioned to address critical needs in the field of infectious diseases.

First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.

Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases. It develops multiple antibiotic drugs intended to combat antimicrobial resistance. The company's technology is focused on targeting the treatment of infectious diseases for both inpatient and outpatient cases, deep expertise in the discovery, development and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance, enabling medical businesses optimal use of products and critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. It was founded in 2018 and is headquartered in San Diego, California.

BioFactura, Inc. is a biotechnology company based in Frederick, Maryland, focused on developing and manufacturing high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs. The company utilizes its patented StableFast Biomanufacturing Platform, which enables the rapid generation of stable NS0 cell lines for biopharmaceutical manufacturing. This platform features a chemically-defined, serum- and cholesterol-free production medium, pre-adapted parental cells, and modular expression vectors, allowing for the development of clonal production cell lines that can yield over one gram of product in less than eight weeks. Additionally, BioFactura offers a range of services, including expression system development, purification process development, microbial and cell culture process development, custom analytical development, and scale-up manufacturing services. The company also provides research, consulting, and contract services, thereby supporting the commercialization of innovative medical products with enhanced speed and quality. Established in 2001, BioFactura aims to meet the growing demands in the biopharmaceutical sector.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. The company focuses on treating Clostridium difficile infection (CDI), with its lead product candidate, ridinilazole, currently in Phase III clinical trials. In addition to ridinilazole, Summit Therapeutics is developing the DDS-01 series aimed at treating infections caused by Neisseria gonorrhoeae and the DDS-04 series for Enterobacteriaceae. The company operates primarily in the United States, Latin America, and Europe, with the intention of establishing new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, Summit Therapeutics is positioned to address critical needs in the field of infectious diseases.

Sanofi Pasteur SA develops, manufactures, and supplies vaccines in France and internationally. The company provides vaccines for bacterial and viral diseases, including pertussis, diphtheria, typhoid fever, poliomyelitis, influenza, and mumps. It has production sites in France, the United States, Canada, China, Thailand, and Argentina. The company was formerly known as Aventis Pasteur S.A. and changed its name to Sanofi Pasteur SA in 2004. The company was founded in 1990 and is headquartered in Lyon, France. The company is headquartered in Lyon, France. Sanofi Pasteur SA operates as a subsidiary of Sanofi-Aventis.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.

Terumo is a healthcare company based in Tokyo that has been a global leader in medical technology for nearly a century. With a workforce of over 25,000 associates, Terumo operates in more than 160 countries, providing a wide range of innovative medical solutions. The company began as a thermometer manufacturer and has since expanded its portfolio to include products for vascular intervention, cardiac surgery, blood transfusion, and cell therapy. Terumo's operations are divided into three main sectors: blood management, cardiac and vascular, and general hospital products. The cardiac and vascular division is the largest revenue generator, offering interventional therapies, surgical systems, and vascular grafts. The general hospital segment encompasses diabetes management, consumer healthcare, and drug-device technologies. Through its diverse offerings, Terumo aims to enhance the quality of care for patients and support healthcare professionals globally.

Spectral AI, Inc. is a predictive analytics company focused on advancing wound care through its proprietary AI algorithms and optical technology. The company has developed the DeepView® Wound Imaging Solution, a multispectral imaging system that has received FDA Breakthrough Designation for burn indications. This innovative technology enables the differentiation between non-healing and healing human tissue that is not visible to the naked eye. By providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers, Spectral AI aims to assist clinicians in making more accurate and timely treatment decisions, ultimately enhancing patient care in the wound care sector.

SIGA is a pharmaceutical company specializing in the development of pharmaceutical solutions for some of the most lethal pathogens – variola (smallpox), Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures.